View Older Stories View More Recent Stories
-
T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors
-
Form SCHEDULE 13D/A Bicara Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Rallybio and Candid Therapeutics announce merger agreement
-
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
-
Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
-
Slate Medicines Launches with $130 Million Series A Financing to Advance Anti-PACAP Therapies for the Prevention of Migraine and Other Headache Disorders
-
Sensei Biotherapeutics acquires Faeth Therapeutics for $200 million
-
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
-
Form SCHEDULE 13D/A Evommune, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D SpyGlass Pharma, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Unicycive Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Surrozen, Inc./DE Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A PALISADE BIO, INC. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A LB PHARMACEUTICALS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Larimar Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Invivyd, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Dec 31
-
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Eledon Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Contineum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Arcellx, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Immunic closes $200 million private placement financing
-
Immunic Announces Closing of Oversubscribed Private Placement Financing
-
Immunic raises up to $400 million in oversubscribed private placement
-
Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
-
ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine
-
Sutro Biopharma prices $110 million stock offering at $13.98 per share
-
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering
-
Form SCHEDULE 13G ALX ONCOLOGY HOLDINGS Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Angitia Biopharmaceuticals Announces $130 Million Series D Financing
-
Apeiron Labs Closes $9.5 Million Series A to Scale Its Global Ocean Data Platform
-
Avalanche Energy Raises $29 Million Following Plasma Physics Breakthroughs
-
Form SCHEDULE 13G Helix Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
-
ALX Oncology prices $150 million stock and warrant offering
-
ALX Oncology Announces Pricing of Underwritten Offering
-
CORXEL Announces $287 million Series D1 Financing to Further Advance Its Cardiometabolic Pipeline including Oral Small Molecule GLP-1 Receptor Agonist
-
Form SCHEDULE 13G Century Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Radence Selects Palm Beach as Location for First Precision Health Hub
-
Kinaset Therapeutics Announces $103 Million Oversubscribed Series B Financing to Advance Novel, Inhaled Therapeutic Candidate for Respiratory Diseases
-
Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Century Therapeutics raises $135 million in private placement
-
Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials
-
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
